WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Vision Mark Biotech
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Sestina Bio | October 17, 2020
Sestina Bio, a new company creating a platform for automated synthetic biology, today announced that it has launched with seed funding from Foresite Capital, General Inception and OMX Ventures. The funds will be used to further the development of its digital cellular engineering and phenotyping platforms and support initial product development. The firm is the first company to launch from incubator Foresite Labs. Practitioners of synthetic biology aim to engineer novel living organisms -- usuall...
Cell and Gene Therapy
Zhongchao Inc. | September 02, 2022
Zhongchao Inc. an internet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patient management service, today announced its newly added business section of oncology and other major disease management which is a part of its development strategy to extend its business model from "Medical-Pharmaceutical" to "Medical-Pharmaceutical-Patient." Utilizing its accumulated exp...
Germany English News | April 08, 2020
Food Microbiology Testing Market report provides an in-depth analysis of the overall market over a period from 2020-2026. The Food Microbiology Testing Market report also provides the market impact and new opportunities created due to the COVID19 catastrophe. The Food Microbiology Testing Market has been segmented based on different types and application. In order to provide a holistic view of the market current and future market, demand has been included in the report. The Food Microbiology Tes...
Diverse Biotech | May 04, 2020
Diverse Biotech, Inc. www.diversebiotech.com has announced the U.S. Food & Drug Administration (FDA) has granted an orphan-drug designation request for one of its investigational new therapies for treatment of newly diagnosed glioblastoma, in conjunction with standard treatment, following adjuvant combined chemo-radiation. Orphan designation qualifies the sponsor of the drug for various development incentives of the ODA, (Orphan Drug Act) including tax credits for qualified clinical te...
Video
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE